Navigation Links
Some antipsychotic drugs may be missing their mark
Date:12/31/2007

COLUMBUS, Ohio Drugs that treat depression, schizophrenia and other psychotic conditions and that target a particular protein on brain cells might not be triggering the most appropriate response in those cells, new research suggests.

The study by researchers at The Ohio State University Medical Center examined the serotonin 2A receptor, a protein on brain cells sensitive to the neurotransmitter serotonin.

This study examined the early chemical events that happen inside neurons when the 2A receptor is stimulated by serotonin and by a synthetic hallucinogenic agent that is thought to mimic serotonin.

The findings, published online in the early edition of the Proceedings of the National Academy of Sciences with an accompanying editorial, show that although both compounds combine with and activate this receptor, they trigger different chemical pathways inside the neuron.

Researchers say that the work could have important implications for the development of drugs that affect the serotonin 2A receptor, a key target in the treatment of several important mental disorders.

This new insight into how serotonin and a hallucinogenic drug affect this serotonin receptor could lead to changes in how new drugs are screened and developed for depression, schizophrenia and other neuropsychiatric disorders, says study leader Laura M. Bohn, an associate professor of pharmacology and psychiatry.

Currently, it is thought that when serotonin binds with the receptor, it sends a signal that activates molecules inside the cell called G proteins.

This study shows, however, that the receptor responds to serotonin by also activating a protein called beta-arrestin inside the cell. The synthetic hallucinogen, on the other hand, causes the receptor to activate only the G proteins. The hallucinogen does not seem to use beta-arrestins to cause its effects.

For this study, Bohn and her colleagues used laboratory-grown cells and a strain of mice that lacked beta-arrestin. The hallucinogen was a hallucinogenic amphetamine called DOI.

When the researchers injected normal (i.e., control) and experimental mice with DOI, both groups showed a head-twitch behavior, a characteristic response in mice to hallucinogens.

But when the mice were given high doses of serotonin, which typically also causes the head-twitch behavior, the behavior occurred in the control animals only, and not in the mice lacking beta-arrestin.

That demonstrates that the signal for serotonin requires beta-arrestin for that biological effect, Bohn says. The synthetic hallucinogen, on the other hand, induces the head-twitch behavior whether beta-arrestin is present or not.

Overall, our findings suggest that the screening of agents intended to be serotonin mimics must also determine if the agent signals through beta-arrestin, Bohn says. That isnt done now.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University
Source:Eurekalert

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Antidepressant as Good as Antipsychotics for Dementia
3. New review suggests caution on drugs to raise good cholesterol
4. Can cancer drugs combine forces?
5. Study provides hope that some transplant patients could live free of antirejection drugs
6. Study provides hope that some transplant patients could live free of anti-rejection drugs
7. RA Drugs Linked to Slight Skin Cancer Risk
8. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
9. Rock N Roll: Sex, Drugs and an Early Exit
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and ... Douglas, an avid reader who lives in the Pacific Northwest with her husband, daughter, ... Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not believe ...
(Date:5/26/2017)... ... , ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible ... creation of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM ... was three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, ... Ellen, hospital employees, and town officials to celebrate the grand opening of the ... by Rendina as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a leader ... – a one-day technology conference in San Diego, CA. , At nVerge 2017, ... to fully utilize and enhance their Sage ERP solutions by providing improved visibility and ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
(Date:5/4/2017)... Mass. and SAN DIEGO ... Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and Scientific ... single-use, self-contained, illuminating medical devices, today announced the launch ... of its OfficeSPEC and ER-SPEC ... the addition of extra-small and extra-large sizes makes OBP ...
Breaking Medicine Technology: